Long-acting therapies continue to gain momentum in HIV
|
The next phase of competition in the HIV market
will be defined not only by achieving viral suppression, but by improving
treatment adherence, ... |
BioNTech Launches mRNA HIV Vaccine Trial
... antiretroviral therapy for at least 12 months will receive four injections. Enrollment will span participants aged 18 to 50 years; those with HIV ... View article...